<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610870</url>
  </required_header>
  <id_info>
    <org_study_id>2007-04-049</org_study_id>
    <nct_id>NCT00610870</nct_id>
  </id_info>
  <brief_title>Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention</brief_title>
  <official_title>Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to determine whether statin pretreatment decrease myocardial
      infarct size in patients with acute myocardial infarction undergoing primary percutaneous
      coronary intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size by SPECT</measure>
    <time_frame>between 5 and 14 days after acute myocardial infarction</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size measured by contrast-enhanced MRI</measure>
    <time_frame>within 14 days after acute myocardial infarction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial blush grade after the procedure</measure>
    <time_frame>immediate after procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete ST resolution</measure>
    <time_frame>at 60 minutes after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac events related to left ventricular dysfunction (death, new-onset sustained hypotension or heart failure, and hospital readmission for left ventricular dysfunction)</measure>
    <time_frame>at 6 months after the procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>atorvastatin 80mg/day before primary coronary intervention</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of chest pain for more than 30 minutes but less than 12 hours after symptom
             onset

          -  ST segment elevation more than 1 mm in two or more contiguous leads or presumably a
             new onset left bundle branch blockage

        Exclusion Criteria:

          -  Cardiogenic shock

          -  History of myocardial infarction

          -  Chronic liver disease

          -  Previous or current statin use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2008</study_first_submitted>
  <study_first_submitted_qc>February 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2008</study_first_posted>
  <last_update_submitted>March 2, 2011</last_update_submitted>
  <last_update_submitted_qc>March 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>HC Gwon, MD,PhD / Professor</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>Myocardial infarct size</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>SPECT</keyword>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

